HomeNewsacute migraine, Biohaven, migraine, RIMEGEPANTBiohaven to present additional Phase 3 Rimegepant Data at AAN 2018

Biohaven to present additional Phase 3 Rimegepant Data at AAN 2018

  • April 20, 2018
  • Posted by: PharmaScroll
  • Category:
No Comments

pharma-1_3554_356

– Data detailing single-dose durable headache relief and recovery of function endpoints from the two pivotal Phase 3 studies of rimegepant, Biohaven’s oral CGRP receptor antagonist.

– Leading migraine thought leaders to discuss potential clinical benefits associated with the rimegepant Phase 3 data

– Webcast of event to be held on Sunday, April 22, 2018 at 6 p.m. Pacific Time

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced that it will hold an investor event concurrently with the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles, from 6:00 p.m. to 7:30 p.m. PT on Sunday, April 22, 2018.  A live webcast of the event may be accessed from the Events page under the Investors section at http://www.biohavenpharma.com, with a replay available for 60 days.

Biohaven recently announced successful achievement of both co-primary endpoints in two pivotal Phase 3 clinical trials of rimegepant, an oral CGRP receptor antagonist for the acute treatment of migraine.  In each trial, rimegepant met the co-primary efficacy endpoints of pain freedom and freedom from most bothersome symptom (MBS) at two hours post-dose.  During the event, a panel of migraine experts will discuss the potential therapeutic benefits associated with the rimegepant Phase 3 clinical trial results.

Topic of Discussion:
Rimegepant Phase 3 Update: Single-Dose Durable Headache Relief and Return to Function Endpoints. Pivotal trial presentation by Dr. Richard Lipton followed by migraine expert panel discussion.

Migraine Expert Panel:

  • DAVID W. DODICK, MD; Mayo Clinic Arizona: Professor, Department of Neurology
  • PETER GOADSBY, MD PhD; King’s College London: Professor of Neurology; and Director, King’s Clinical Research Facility, King’s College Hospital
  • SUSAN HUTCHINSON, MD; Orange County Migraine & Headache Center: Director; President, Headache Cooperative of the Pacific
  • RICHARD B. LIPTON, MD; AlbertEinstein College of Medicine: Edwin S. Lowe Professor and Vice Chair of Neurology; Professor of Epidemiology and Population Health; Director, Montefiore Headache Center

Webcast
Biohaven will host a live video webcast of the event starting at 9:00 p.m. ET (6:00 p.m. PT). To access the video webcast with slides, please visit the “Events” page in the Investors section of the Company’s website at http://investors.biohavenpharma.com/events. A replay will be available on the Company’s website after the event. Institutional investors and analysts may RSVP to attend in person by contacting bkorb@troutgroup.com.

 

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/

 

News Source: Biohaven Website

Image Source: https://www.moneycontrol.com/news/business/companies/alembic-pharma-gets-us-fda-nod-for-anti-migraine-drug-918889.html